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A B S T R A C T
Introduction: Ageing and several age-related chronic conditions including obesity, insulin resistance and hy-
pertension are associated with mitochondrial dysfunction and represent independent risk factors for atrial ﬁ-
brillation (AF).
Materials and methods: Atrial arrhythmogenesis was investigated in Langendorﬀ-perfused young (3–4 month)
and aged (> 12 month), wild type (WT) and peroxisome proliferator activated receptor-γ coactivator-1β deﬁ-
cient (Pgc-1β−/−) murine hearts modeling age-dependent chronic mitochondrial dysfunction during regular
pacing and programmed electrical stimulation (PES).
Results and discussion: The Pgc-1β−/− genotype was associated with a pro-arrhythmic phenotype progressing
with age. Young and aged Pgc-1β−/− hearts showed compromised maximum action potential (AP) depolar-
ization rates, (dV/dt)max, prolonged AP latencies reﬂecting slowed action potential (AP) conduction, similar
eﬀective refractory periods and baseline action potential durations (APD90) but shortened APD90 in APs in
response to extrasystolic stimuli at short stimulation intervals. Electrical properties of APs triggering arrhythmia
were similar in WT and Pgc-1β−/− hearts. Pgc-1β−/− hearts showed accelerated age-dependent ﬁbrotic change
relative to WT, with young Pgc-1β−/− hearts displaying similar ﬁbrotic change as aged WT, and aged Pgc-1β−/−
hearts the greatest ﬁbrotic change. Mitochondrial deﬁcits thus result in an arrhythmic substrate, through slowed
AP conduction and altered repolarisation characteristics, arising from alterations in electrophysiological prop-
erties and accelerated structural change.
1. Introduction
Atrial ﬁbrillation (AF) aﬀects 1–3% of the population in the devel-
oped world (DeWilde et al., 2006; Friberg and Bergfeldt, 2013; Majeed
et al., 2001) and is associated with signiﬁcant morbidity and mortality,
including ﬁve-fold increases in risks of stroke (Wolf et al., 1991) and
signiﬁcant increases in risks of all-cause mortality (Benjamin et al.,
1998; Chamberlain et al., 2015; Friberg et al., 2007). Recent studies
forecast a substantial increase in the incidence and prevalence of AF in
the coming decades, with potentially 9 million cases in the United
States (Miyasaka et al., 2006) and 18 million in Europe by 2060 (Krijthe
et al., 2013), underpinning its recognition as a global epidemic. Its
prevalence appears to a great extent to be a function of age, aﬀecting
0.1% of individuals under the age of 55, reaching 20% of those above
the age of 80 (Go et al., 2001; Zoni-Berisso et al., 2014). The
aetiological signiﬁcance of this age-related incidence or indeed the
mechanisms underlying the initiation and perpetuation of AF remain
incompletely explained. It is however clear that AF is a dynamic pro-
cess, which at its inception is characterised by ﬂeeting episodes of the
abnormal rhythm triggered by focal ectopic activity in the pulmonary
vein sleeves (Haïssaguerre et al., 1998). With time, these episodes be-
come more protracted and eventually permanent through progressive
electrical and structural remodeling ultimately producing a tissue
substrate itself conducive to arrhythmia maintenance. Treatment in
these latter stages is far less eﬃcacious (Cappato et al., 2010), high-
lighting the need to target therapies to the upstream processes.
There is now growing appreciation for roles of metabolic, and in
particular mitochondrial, dysfunction in the pathogenesis of AF.
Mitochondrial dysfunction is a recognised feature of ageing (Sun et al.,
2016) as well as a number of the constituents of the metabolic
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syndrome including obesity (Bournat and Brown, 2010), insulin re-
sistance (Patti and Corvera, 2010) and hypertension (Dikalov and
Ungvari, 2013), all recognised risk factors for AF (Menezes et al., 2013).
Abnormal mitochondrial structure and function have been reported in
animal models of AF (Ausma et al., 1997; Morillo et al., 1995). More-
over, analysis of cardiomyocytes from human patients with AF de-
monstrate increased DNA damage (Lin et al., 2003; Tsuboi et al., 2001),
structural abnormalities (Bukowska et al., 2008) and evidence of im-
paired function (Ad et al., 2005; Lin et al., 2003). Whether the observed
mitochondrial abnormalities are a cause or consequence of AF, and the
mechanisms through which these changes occur remain unclear.
Disruptions in normal mitochondrial activity are known to be pro-
arrhythmic, through reduced provision of ATP and/or aberrant pro-
duction of reactive oxygen species (ROS), and therefore are a potential
upstream mediator of arrhythmogenesis (Faivre and Findlay, 1990;
Fosset et al., 1988; Manning et al., 1984). Much of this work has
however been in the context of acute, profound mitochondrial im-
pairment during ischaemia-reperfusion and focussed on mechanisms of
ventricular arrhythmias. Interestingly, Chen & colleagues recently de-
monstrated increased ectopic activity, burst ﬁring and shortening of the
action potential duration (APD) in pulmonary veins and left atria of
rabbit hearts subjected to ischaemia-reperfusion (Lin et al., 2012).
Moreover, sustained arrhythmias are generally thought to occur
through maladaptive changes in the electrophysiological properties of a
tissue, promoting the formation of re-entrant circuits. Such would arise
through slowed conduction of the depolarising wavefront and/or
shortening of the eﬀective refractory period (ERP). Indeed, time-de-
pendent alterations in both atrial conduction (Gaspo et al., 1997a;
Zheng et al., 2016) and repolarisation (Bosch et al., 1999; Daoud et al.,
1996; Gaspo et al., 1997b) properties have been reported in animal
models and human AF. Reductions in the inward sodium currents (INa),
a major determinant of conduction velocity (King et al., 2013a), have
been reported secondary to excess mitochondrial ROS production (Liu
et al., 2010). Gap junction activity is also known to be similarly sen-
sitive to mitochondrial function (Li et al., 2016; Sovari et al., 2013) and
may also contribute to conduction slowing. Mitochondrial impairment
and cardiac oxidative stress in general are also recognised to reduce
action potential durations and ERPs (Chen et al., 2007; Kurokawa et al.,
2011; Lesnefsky et al., 1991), both of which favour re-entry and ar-
rhythmia.
The electrophysiological sequelae of chronic mitochondrial dys-
function have however been challenging to study, confounded by the
early and often terminal development of contractile dysfunction.
However, such evaluation now appears feasible in murine models
lacking members of the peroxisome proliferator activated receptor-γ
coactivator-1 (PGC-1) family of transcriptional coactivators. The PGC-1
family include PGC-1α and PGC-1β, which though found with a rea-
sonable degree of ubiquity, are preferentially expressed in tissues with
high oxidative capacity such as the heart, brain and skeletal muscle
(Riehle and Abel, 2012) and act as key regulators of mitochondrial mass
and function (Finck and Kelly, 2006; Lin et al., 2005). In cardiac cells,
the PGC-1 coactivators interact with nuclear respiratory factor-1, es-
trogen related receptor-α and peroxisome proliferator-activated re-
ceptor-α, leading to increased mitochondrial biogenesis (Huss et al.,
2004; Vega et al., 2000). They also act to upregulate expression of
nuclear and/or mitochondrial encoded mitochondrial proteins involved
in the tricarboxylic acid cycle, fatty acid β–oxidation and components
of the oxidative phosphorylation complex (Arany et al., 2005). PGC-1
protein expression itself is increased by upstream signals such as those
arising from cold exposure and aerobic exercise, thereby serving as a
link between cellular energy stores and external stimuli ultimately co-
ordinating mitochondrial activity with cellular energy demands
(Sonoda et al., 2007). Interestingly, their expression levels are found to
be reduced in obesity, insulin resistance, type II diabetes mellitus and
ageing, correlating with the mitochondrial dysfunction that is seen in
these conditions and implicating it in the their pathogenesis (Dillon
et al., 2012; Leone and Kelly, 2011; Mootha et al., 2003).
Murine hearts lacking either Pgc-1α or Pgc-1β do not develop car-
diac failure under conditions of baseline activity. Homozygous deﬁ-
ciency of Pgc-1α is associated with a mild baseline cardiac phenotype
with no overt contractile dysfunction, but cardiac failure does develop
following transverse aortic banding (Arany et al., 2005). Similarly,
genetic ablation of Pgc-1β does not appear to be detrimental to cardiac
function at baseline, but adrenergic challenge elicits blunted rate re-
sponses potentially reﬂecting underlying electrophysiological abnorm-
alities (Lelliott et al., 2006). Indeed, Langendorﬀ-perfused Pgc-1β−/−
murine hearts displayed features consistent with increased vulner-
ability to ventricular arrhythmia, with greater episodes of action po-
tential alternans, a recognised harbinger for arrhythmia, and more
frequent episodes of ventricular tachycardia during programmed elec-
trical stimulation (Gurung et al., 2011). Isolated cardiomyocytes in the
latter study showed altered patterns of ion channel expression, spon-
taneous diastolic Ca2+ transients, and pro-arrhythmic after-depolar-
isation events. The electrophysiological alterations and any associated
change in arrhythmic propensity in the atria of these hearts have hi-
therto not been investigated.
The present study investigates the atrial electrophysiological prop-
erties secondary to chronic mitochondrial insuﬃciency in murine
hearts lacking Pgc-1β. The phenotypic eﬀects of such a mitochondrial
deﬁcit are likely to be cumulative, evolving with advancing age. Young
and aged WT and genetically modiﬁed hearts were therefore studied at
both the whole heart and cellular level, assessing arrhythmic tendency




This research has been regulated under the Animals (Scientiﬁc
Procedures) Act 1986 Amendment Regulations 2012 following ethical
review by the University of Cambridge Animal Welfare and Ethical
Review Body (AWERB). Age-matched wild type (WT) and Pgc-1β−/−
mice with an inbred C57/B6 genetic background were used for the
study. Pgc-1β−/− mice were generated using a triple LoxP targeting
vector as previously described (Lelliott et al., 2006). Mice aged between
3 and 4 months were classiﬁed as young, and aged mice were deﬁned as
those older than 12 months. Mice were housed in plastic cages within a
temperature-controlled room maintained at 21 ± 1 °C and subjected
to 12 h dark/light cycles. Sterile rodent chow (RM3 Maintenance Diet,
SDS, Witham, Essex, UK) and water were available ad libitum.
2.2. Experimental solutions
All buﬀering media utilised in the study were based on Krebs-
Henseleit (KH) solution, containing NaCl (119 mM), NaHCO3 (25 mM),
KCl (4 mM), MgCl2 (1 mM), KH2PO4 (1.2 mM), CaCl2 (1.8 mM), glucose
(10 mM) and sodium pyruvate (1.8 mM), pH adjusted to 7.4 and bub-
bled with 95% O2/5% CO2 (British Oxygen Company, Manchester, UK).
All chemical reagents were purchased from Sigma-Aldrich (Dorset,
Poole, UK) except where otherwise indicated. Hearts were electro-
mechanically uncoupled using blebbistatin (20 μM, Selleckchem,
Houston, USA) to minimize motion artifact during the microelectrode
studies, permitting stable impalement of the cardiomyocyte.
2.3. Whole heart Langendorﬀ preparation
Electrocardiograph and microelectrode studies were performed
using a horizontal Langendorﬀ perfusion system adapted for the murine
heart incorporated into a Faraday cage, together with a light micro-
scope (objective × 5, eyepiece × 5, W. Watson and Sons Limited,
London, UK), custom built head stage and a warmed bath superfused
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with the buﬀering media. All equipment was electrically insulated. The
stimulating and recording electrodes were positioned at appropriate
positions on the right and left atrium respectively using two precision
micromanipulators (Prior Scientiﬁc Instruments, Cambridge, UK).
Mice were anticoagulated with heparin sodium 200 IU (Sigma-
Aldrich, Poole, UK) prior to sacriﬁce, administered into the intra-peri-
toneal space with a 27G hypodermic needle. Following an interval of
10 min, mice were killed by cervical dislocation (Schedule 1: UK
Animals (Scientiﬁc Procedures) Act (1986)), a sternotomy and cardi-
ectomy rapidly performed and the excised heart placed in ice-cold bi-
carbonate-buﬀered KH solution. The proximal segment of the aorta was
identiﬁed and cannulated with a modiﬁed 21G hypodermic needle, and
secured in place with an aneurysm clip (Harvard Apparatus, Kent, UK)
and a 5-0 braided silk suture. The cannulated heart was mounted on to
the Langendorﬀ apparatus and retrogradely perfused with KH solution
at a constant ﬂow rate of 2.05 ml min−1 by a peristaltic pump
(MINIPULS3, Gilson, Luton, UK) passing ﬁrst through 200 μm and 5 μm
Millipore ﬁlters (Millipore, Watford, UK) and maintained at 37 °C by a
water jacket and circulator (model C-85A, Techne, Cambridge, UK).
Upon perfusion, hearts were selected for experimentation if they de-
monstrated sustained intrinsic activity with a basic cycle length
(BCL) < 200 ms and 1:1 atrioventricular conduction (AV) for 10 min.
Preparations meeting these criteria were subsequently perfused with
150 ml KH solution containing 20 μM blebbistatin and then normal KH
solution throughout the remainder of the study.
2.4. Volume conductor electrocardiographic recordings
Whole heart volume conductor electrocardiographic (ECG) record-
ings were taken concurrently with intracellular recordings to distin-
guish between isolated cellular and generalised atrial phenomena. Two
unipolar ECG leads were immersed into the warmed bath ﬂanking the
right and left atria respectively. Signals were ampliﬁed using a model
NL104A ampliﬁer (NeuroLog; Digitimer, Hertfordshire, UK), ﬁltered at
low and high cut-oﬀ frequencies of 5 and 500 Hz (model NL125/126
ﬁlter) and digitized using a model 1401 interface (Cambridge
Electronic Design) for analysis with Spike II software (Cambridge
Electronic Design).
2.5. Whole heart intracellular microelectrode recordings
Glass micropipettes were drawn from 1.2 mm outer diameter and
0.69 mm internal diameter borosilicate glass (Harvard Apparatus,
Cambridge, UK) using a homebuilt microelectrode puller, and cut above
the shoulders to an appropriate length. The microelectrodes were
backﬁlled with 3 M KCl immediately before use, with tip resistances
ranging between 15 and 25 MΩ. The ﬁlled microelectrode was mounted
on to a right-angled microelectrode holder connected to a high-input
impedance direct-current microelectrode ampliﬁer system (University
of Cambridge, Cambridge, UK). Intracellular voltage was measured
relative to that of the Ag/AgCl reference electrode. AP recordings were
used for analysis if obtained from an impalement associated with the
abrupt appearance of a resting membrane potential (RMP) between
−65 mV and −90 mV, stable and normal AP morphology and an AP
amplitude> 75 mV.
Hearts were placed in the anatomical position within the bath with
the left atrium (LA) reﬂected back and ﬁxed in position using three A1
insect pins. A bipolar platinum-coated stimulating electrode (NuMed,
New York, USA) was positioned against the epicardial surface of the
right atrium, pacing the heart using square-wave stimuli of 2 ms
duration using a constant voltage stimulator (model DS2A-Mk.II,
Digitimer, Welwyn Garden City, Herts., UK) controlled by Spike II
software (Cambridge Electrical Design, Cambridge, UK) and delivering
a voltage that was twice the diastolic excitation threshold plus 0.5 mV.
The initial experiments examined the hearts under conditions of regular
pacing at a basic cycle length (BCL) of 125 ms (8 Hz). Hearts were then
studied using a programmed electrical stimulation (PES) protocol
comprising drive trains of eight regularly paced (S1) beats at a BCL of
125 ms, followed by an isolated premature extra stimulus (S2) every
ninth beat. The S2 stimulus was imposed at progressively shortening
S1-S2 coupling intervals, initially being 89 ms and reducing by 1 ms
every subsequent cycle to a ﬁnal coupling interval of 5 ms. The protocol
was terminated upon establishment of the atrial eﬀective refractory
period (ERP), deﬁned as the ﬁrst S1-S2 coupling interval at which the
S2 stimulus failed to successfully elicit an AP, or sustained arrhythmia
was observed.
2.6. Quantiﬁcation of AP parameters and arrhythmic incidence
The electrophysiological parameters were calculated from each AP
individually and averaged across the protocol to give an overall mean
for each heart. The AP amplitude was measured from the baseline to the
peak voltage excursion and the AP duration was measured as 90% re-
covery to baseline (APD90) (Fig. 1). AP latencies were measured as the
time elapsed between the pacing stimulus and peak of the AP. Max-
imum rates of AP depolarization (dV/dt)max were calculated from the
diﬀerentiated intracellular AP waveform. The incidence of abnormal
atrial rhythms were determined from the regular pacing and PES pro-
tocols, correlating cellular phenomena with tissue-level activity. Iso-
lated non-triggered APs were classiﬁed as ectopic beats, two successive
non-triggered beats termed a couplet and atrial tachycardia (AT) was
deﬁned as an episode consisting of≥3 consecutive non-triggered beats.
2.7. Quantiﬁcation of cardiac ﬁbrosis
The quantiﬁcation of cardiac ﬁbrosis was performed as previously
described (Jeevaratnam et al., 2011). Brieﬂy, the excised heart was ﬁrst
ﬂushed with KH solution and then perfused for ﬁve minutes with 4%
buﬀered paraformaldehyde before being immersed in the paraf-
ormaldehyde overnight. Following the ﬁxation process, longitudinal
cardiac sections were cut and subjected to routine tissue processing and
paraﬃn embedding. Serial sections of 7 μm thickness were then taken
and stained with picrosirius red for ﬁbrotic change. All sections were
subsequently viewed, magniﬁed and digitally acquired using the Nano
Zoomer 2.0 Digital Pathology system (Hamamatsu, Hertfordshire, UK).
A custom made 17 cm× 30 cm morphometric grid was superimposed
on each magniﬁed photomicrograph and each successive 1 cm× 1 cm
Fig. 1. Basic measures of atrial action potential (AP) propagation, activation and re-
covery. AP amplitude was measured from the baseline to the peak voltage excursion. AP
duration was measured as 90% recovery to baseline (APD90), and AP latencies were
measured as the time elapsed between the pacing stimulus and peak of the AP. Maximum
rates of depolarization (dV/dt)max were calculated from the ﬁrst diﬀerential of the in-
tracellular AP waveform.
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square, corresponding to 0.2 mm× 0.2 mm area of tissue, was scored
ﬁrst for the presence or absence of cardiac tissue, and in turn for pre-
sence of ﬁbrosis. The degree of ﬁbrosis was quantiﬁed as the proportion
of squares occupied by cardiac tissue showing evidence of ﬁbrotic
change. The analysis was performed independently by two investigators
blinded to the animal genotype and age, and an inter-class correlation
coeﬃcient analysis (ICC) was performed to assess the consistency of
their results, which can be interpreted as follows: 0–0.2 indicates poor
agreement; 0.3–0.4 indicates fair agreement; 0.5–0.6 indicates moderate
agreement; 0.7–0.8 indicates strong agreement; and>0.8 indicates al-
most perfect agreement.
2.8. Statistical analysis
Data from AP recordings were analysed using a custom written
programme in the python programming language and all statistical
analysis performed in the R programming language (R Core Team,
2015). Discrete incidences of abnormal rhythms were separated ac-
cording to their type and the pacing protocol, either regular pacing or
PES, in which they were observed. As often multiple episodes of AT
were seen during a single protocol, the propensity to arrhythmia was
expressed as protocols with one or more episodes of AT expressed re-
lative to the total number studied, and compared using the Fisher Exact
Test. Parameters describing electrophysiological properties measured
during regular pacing were compared using a two-way analysis of
variance (ANOVA) testing for signiﬁcant eﬀects of genotype, ageing,
and an interaction between the two. Where the F-ratio yielded a sig-
niﬁcant result, post-hoc Tukey honestly signiﬁcant testing was per-
formed. Similar electrophysiological measurements from PES protocols
were compared in two separate ways. Firstly, diﬀerences spanning the
duration of the protocol were compared using ANOVA analysis of area
under the curve (AUC) values for each group. To further evaluate the
temporal nature of any diﬀerences between groups, mean protocol start
and protocol end values for each experimental group were compared in
the same manner as data from the regular pacing protocol. Where the
data from PES protocols was normalised, the corresponding data from
regular pacing was used as reference values. Data are expressed as
mean ± standard error of the mean (SEM), and in all cases a p < 0.05
was taken to be signiﬁcant, with application of Bonferroni correction
where appropriate.
3. Results
The experiments evaluated the inﬂuence of ageing and mitochon-
drial dysfunction, through homozygous deﬁciency in Pgc-1β, upon at-
rial arrhythmic tendency and the associated electrophysiological al-
terations. Simultaneous ECG and intracellular microelectrode readings
were recorded from Langendorﬀ perfused WT and Pgc-1β−/− hearts
and the presence or otherwise of an arrhythmic substrate was then
correlated with structural changes at the organ level.
3.1. Pgc-1β−/− hearts develop an age-related arrhythmic phenotype
Volume conductor ECGs and intracellular action potential (AP) re-
cordings were ﬁrst obtained from Langendorﬀ perfused hearts during
regular pacing at a BCL of 125 ms (8 Hz) mimicking murine resting
heart rates, thus enabling quantiﬁcation of occurrence of spontaneous
arrhythmia and electrophysiological characterisation under conditions
of baseline activity. Fig. 2(a(i)) demonstrates a typical ECG recording
from a young WT heart during regular 8 Hz pacing and Fig. 2(a(ii)) is
the simultaneous intracellular AP from a left atrial (LA) cardiomyocyte.
The intracellular recordings conﬁrmed normally polarised resting
membrane potentials (RMPs) statistically indistinguishable between
groups (young WT: −76.62 ± 1.37 mV, n = 26; aged WT:
−76.72 ± 1.47 mV, n = 27, young Pgc-1β−/−: -75.82 ± 0.68 mV,
n = 34; aged Pgc-1β−/−: −77.43 ± 1.49 mV, n = 25). Similarly, AP
amplitudes conﬁrmed positive AP overshoots through all experimental
groups, consistent with intracellular recordings from viable atrial car-
diomyocytes in situ, though AP amplitudes were marginally lower in
aged Pgc-1β−/− hearts (young WT: 96.76 ± 1.14 mV, n = 26; aged
WT: 96.92 ± 1.55 mV, n = 27, young Pgc-1β−/−: 93.19 ± 1.12 mV,
n = 34; aged Pgc-1β−/−: 91.21 ± 1.63 mV, n = 25, p < 0.05). No
spontaneous arrhythmias were observed from hearts in any experi-
mental group during the regular pacing protocols.
Hearts were then subjected to a programmed electrical stimulation
(PES) protocol consisting of repeated cycles of nine beats, of which the
ﬁrst eight (S1) beats were separated by a regular interval of 125 ms and
the ninth was a premature extra stimulus (S2) at an initial S1-S2 cou-
pling interval of 89 ms that was decremented by 1 ms with each suc-
cessive cycle. This permitted evaluation of the arrhythmic tendency of
hearts in response to provocation with an imposed premature S2 beat,
the alterations in electrophysiological parameters with varying cou-
pling intervals, and diﬀerences in atrial eﬀective refractory periods
(ERPs) between groups. Fig. 2(b) shows typical (i) ECG and (ii) AP
recordings during PES pacing from a young WT heart with a refractory
as opposed to an arrhythmic outcome. Several abnormal rhythms were
observed during PES pacing as exempliﬁed in Fig. 3. These were trig-
gered by the S2 premature stimulus and included isolated ectopic beats
(Fig. 3(a)), paired beats termed a couplet (Fig. 3(b)) and episodes of
atrial tachycardia (AT) deﬁned as three or more consecutive non-sti-
mulated beats (Fig. 3(c)).
Fig. 2. Typical recordings from Langendorﬀ-perfused WT hearts during regular pacing
and programmed electrical stimulation. Electrocardiograph (ECG) (i) and left atrial in-
tracellular action potential (AP) recordings (ii) during (a) regular 8 Hz pacing and (b) a
protocol imposing programmed electrical stimulation with a refractory outcome. The
timings of stimulus delivery are given by the dashed bar above the AP recordings, and
corresponding stimulation artefacts can be seen on the ECG and AP traces, preceding the
respective complexes. In panel (B), arrows indicate the imposition of S2 extrastimuli. The
ﬁrst two S2 stimuli trigger APs, whereas the third S2 stimulus fails to elicit a response,
thus representing a refractory outcome.
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Table 1 summarises the number of episodes of the diﬀerent ab-
normal rhythms observed during PES, stratiﬁed by experimental group.
Incidences of atrial tachycardia (AT) were signiﬁcantly greater in aged
Pgc-1β−/− hearts compared to any other group with respect to the
overall proportion aﬀected (p < 0.05, Fisher Exact Test) and the
number of arrhythmic events per individual heart, suggesting an ar-
rhythmic phenotype associated with mitochondrial dysfunction that
progresses with age. AT was more frequently observed in the aged Pgc-
1β−/− group compared to either of the WT groups, with no diﬀerence
in incidence observed between the young and aged WT groups. Al-
though a similar proportion of young and aged WT hearts were ar-
rhythmic, arrhythmic event rates were higher in the latter further re-
inforcing an eﬀect of age upon arrhythmic risk. Thus ANOVA of mean
AT events per heart demonstrated a signiﬁcant eﬀect of genotype
(F= 7.13, p < 0.01) with Pgc-1β−/− hearts having higher event rates
and age (F= 7.26, p < 0.01), but no interactive eﬀect (F= 2.37,
p > 0.05). Post hoc Tukey tests demonstrated signiﬁcant diﬀerences in
rates of AT between aged Pgc-1β−/− hearts and young WT hearts
(p < 0.01), aged WT hearts (p < 0.05) and young Pgc-1β−/− hearts
(p < 0.05).
This increased propensity to AT is further highlighted on analysis of
the critical coupling intervals, given by the S1-S2 coupling interval at
which arrhythmia was triggered as shown in Fig. 4. Episodes of AT in
WT hearts (Fig. 4(a) and (b)) were triggered predominantly at latter
parts of the PES protocol corresponding to shorter S1-S2 coupling in-
tervals. In contrast Pgc-1β−/− hearts developed arrhythmias at earlier
stages of the protocol and over a wider range of coupling intervals
(Fig. 4(c) and (d)), with aged Pgc-1β−/− hearts particularly appearing
vulnerable throughout the duration of the protocol. The mean critical
coupling interval was longer in Pgc-1β−/− hearts (F= 8.35, p
< 0.01) and aged hearts (F= 3.93, p < 0.05), though no interactive
eﬀect was observed (F= 0.004, p > 0.05). Post hoc analysis demon-
strated signiﬁcant diﬀerences between aged Pgc-1β−/− and young WT
hearts (p < 0.05) and a trend to signiﬁcance between aged Pgc-1β−/−
and aged WT hearts (p < 0.10).
3.2. Action potential parameters during regular pacing
These diﬀering arrhythmic proﬁles were next compared with elec-
trophysiological parameters corresponding to AP initiation, propaga-
tion and recovery during regular pacing at 8 Hz. AP initiation was
measured ﬁrst through maximum rates of AP depolarisation (dV/dt)max,
derived from left atrial intracellular microelectrode recordings. (dV/
dt)max measurements quantify the depolarisation of the cardiomyocyte
membrane capacitance by regenerative inward Na+ current.
Reductions in (dV/dt)max are known to correlate with compromised
conduction velocity of an AP wavefront, potentially providing a sub-
strate permissive to AP re-entry and arrhythmia. Pgc-1β−/− hearts
showed signiﬁcantly lower values of (dV/dt)max compared to WT
(F= 18.41, p < 0.001) but there was no eﬀect of age (F= 0.17,
p > 0.05) or interaction between age and genotype (F= 0.001,
p > 0.05). On post hoc Tukey testing, each Pgc-1β−/− group, whether
young or aged, showed signiﬁcantly lower (dV/dt)max values than ei-
ther of the WT groups (Table 2).
AP conduction through respective cardiac chambers is determined
not only by the properties of the inward Na+ current, reﬂected in the
cellular (dV/dt)max values, but also the total membrane capacitance and
resistance (King et al., 2013a). AP propagation was therefore further
assessed through comparisons of AP latency times, measured as the
time intervening between stimulus delivery at the right atrial pacing
site and the peak AP voltage measured at the left atrial (LA) recording
site. In all experiments, the stimulating electrode was consistently po-
sitioned at the posterior aspect of the RA and recordings were made
from the central region of the LA, minimising variability in distances
between the respective electrodes. ANOVA of AP latency times de-
monstrated signiﬁcant eﬀects of genotype (F= 9.91, p < 0.01), age
(F= 5.32, p < 0.05) and an interaction of the two (F= 12.47,
Fig. 3. Examples of intracellular records of abnormal rhythms elicited by S2 premature
stimuli during PES pacing, including (a) isolated ectopic beats, (b) paired beats forming
couplets and (c) episodes of atrial tachycardia (AT) deﬁned as three or more consecutive
non-stimulated beats. The timings of stimulus delivery are given by the dashed bar above
the AP recordings and arrows indicate the onset of the abnormal rhythm.
Table 1
Summary of arrhythmic events during programmed electrical stimulation.
Experimental
group
No. that developed AT (n/
total)
Ectopic beats (mean ± SEM) Couplets (mean ± SEM) AT (mean ± SEM) Critical coupling interval (mean ± SEM)
Young Wild Type 5/27 1.48 ± 0.50 0.41 ± 0.26 0.26** ± 0.11 28.71 # ± 3.46
Aged Wild Type 4/27 0.79 ± 0.53 1.17 ± 0.62 0.48† ± 0.36 32.71 ± 4.21
Young Pgc-1β−/− 11/34 1.22 ± 0.47 0.42 ± 0.21 0.86‡ ± 0.35 35.70 ± 1.35
Aged Pgc-1β−/− 12/25* 1.64 ± 0.66 1.28 ± 0.55 2.64**,†,‡ ± 0.70 39.39 # ± 1.12
Symbols denote signiﬁcant diﬀerence based on post hoc analysis, performed if the F value from two-way ANOVA was signiﬁcant. Single, double and triple symbols denote p < 0.05,
p < 0.01 and p < 0.001 respectively.
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p < 0.001). As detailed in Table 2, these diﬀerences were driven by
young WT hearts, which had signiﬁcantly shorter AP latency times than
aged WT hearts (p < 0.001), young Pgc-1β−/− hearts (p < 0.001),
and aged Pgc-1β−/− hearts (p < 0.01), There was no signiﬁcant dif-
ference between the aged WT hearts and either of the Pgc-1β −/−
groups.
Pro-arrhythmic tissue substrate has also been associated with al-
tered repolarisation associated with action potential shortening or
prolongation (Killeen et al., 2007; Sabir et al., 2007a, 2007b). Elec-
trophysiological parameters describing repolarisation are given in
Table 2. No diﬀerences in APD at 90% repolarisation (APD90) were
found during regular 8 Hz pacing either through eﬀects of genotype
(F= 1.07, p > 0.05), age (F= 0.001, p > 0.05) or an interaction of
the two (F= 0.20, p > 0.05). Repolarisation properties were further
assessed through measurement of the eﬀective refractory period (ERP)
obtained from the PES protocol, deﬁned as the longest S1-S2 coupling
interval at which the S2 stimulus failed to trigger an AP. The ERP
generally correlates with the APD, and in keeping with this no diﬀer-
ences between groups were observed when compared according to
genotype (F= 3.36, p > 0.05) or age (F= 0.04, p > 0.05).
3.3. Action potential parameters following premature extrasystolic stimuli
The trigger-substrate model of arrhythmogenesis involves initiation
of the abnormal rhythm through an arrhythmogenic trigger, such as an
extrasystole, occurring within a pro-arrhythmic substrate capable of
sustaining the arrhythmia (Antzelevich et al., 1999, Kalin et al., 2010).
The PES protocol consisted of pulse trains of S1 beats 125 ms apart,
punctuated every ninth beat by a premature S2 stimulus, mimicking
such triggering extrasystoles. The external application of these pre-
mature beats thus controlled for incidence of ectopic stimuli between
groups and so assessed for the presence of such an arrhythmogenic
substrate.
Fig. 5(a(i)) plots mean (dV/dt)max values for APs triggered by S2
stimuli across the range of coupling intervals explored during the PES
protocol. All experimental groups displayed the expected progressively
reduced (dV/dt)max values with shortening of the S1-S2 coupling in-
terval. In common with ﬁndings obtained during regular pacing, an
analysis of the areas beneath the data curve (AUC) demonstrated that
the overall rates of depolarisation were signiﬁcantly higher in WT than
Pgc-1β−/− hearts (F= 6.41, p < 0.05) (Table 3); there were no eﬀects
of age (F= 0.84, p > 0.05) or interacting eﬀects of genotype and age
(F= 0.27, p > 0.05). The diﬀerence between WT and Pgc-1β−/−
hearts was most pronounced at the beginning of the protocol (Fig. 5(a
(ii))) (ANOVA − genotype: F= 13.19, p < 0.001; age: F= 0.15,
p > 0.05; interaction: F= 0.002, p > 0.05) and was of a similar
magnitude as had been observed during 8 Hz pacing. On post hoc
analysis, each WT group showed signiﬁcantly higher (dV/dt)max values
compared against either of the Pgc-1β−/− groups. In contrast, no dif-
ference in (dV/dt)max values was observed at the shortest coupling
Fig. 4. Stratiﬁcation of the occurrence of AT episodes by critical coupling intervals in young ((a), (c)) and old ((b), (d)), WT ((a), (b)) and Pgc-1β−/− hearts ((c), (d)). Pgc-1β−/− hearts
display vulnerability to arrhythmia earlier, and through wider range of S1-S2 coupling intervals.
Table 2
Action potential properties in WT and Pgc-1β-/- hearts during regular 8 Hz pacing.
Experimental group (dV/dt)max (V s−1) AP latency (ms) APD90 duration (ms) Eﬀective refractory period (ms) Wavelength
Young Wild Type 171.06*, † ± 6.60 17.69***, †††, ‡‡ ± 0.23 24.87 ± 1.18 26.62 ± 1.27 4.21*, † ± 0.25
Aged Wild Type 171.73‡‡, # ± 5.15 23.93*** ± 1.24 25.51 ± 1.59 27.33 ± 1.77 4.34‡‡, ## ± 0.29
Young Pgc-1β-/- 141.28*, ‡‡ ± 7.19 24.61††† ± 0.65 23.97 ± 0.93 29.82 ± 0.54 3.28*, ‡‡ ± 0.16
Aged Pgc-1β-/- 142.39†, # ± 8.08 23.48‡‡ ± 1.66 23.28 ± 2.16 28.33 ± 1.33 3.15†, ## ± 0.25
All values are given as mean (± SEM).
Symbols denote signiﬁcant diﬀerence based on post hoc analysis, performed if the F value from two-way ANOVA was signiﬁcant. Single, double and triple symbols denote p < 0.05,
p < 0.01 and p < 0.001 respectively.
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intervals at the end of the protocol, whether tested for eﬀects of gen-
otype (F= 0.09, p > 0.05), age (F= 0.18, p > 0.05) or interaction
between these factors (F= 0.31, p > 0.05).
Similar plots for AP latencies are given in Fig. 5(b(i)) and 5(b(ii)). In
keeping with ﬁndings during regular 8 Hz pacing and the observed
diﬀerences in (dV/dt)max values, AP latency times were signiﬁcantly
prolonged in Pgc-1β−/− hearts when surveyed through the entirety of
the protocol on AUC analyses (F= 12.98, p < 0.001), but there were
no independent eﬀects of age (F= 1.11, p > 0.05) or compound ef-
fects of age and genotype (F= 1.36, p > 0.05). Young WT hearts had
signiﬁcantly shorter AP latency times compared to young Pgc-1β−/−
hearts (p < 0.01) and aged Pgc-1β−/− hearts (p < 0.05) on post hoc
testing. ANOVA of AP latencies at the longest S1-S2 intervals demon-
strated signiﬁcant eﬀects of genotype (F= 19.23, p < 0.001), age
(F= 4.79, p < 0.05) and interacting eﬀects of genotype and age
(F= 6.12, p < 0.05). Here the AP latency times for young WT hearts
were signiﬁcantly shorter than all other groups including aged WT
(p < 0.01), young Pgc-1β−/− (p < 0.001) and aged Pgc-1β−/− hearts
(p < 0.001). AP latencies progressively lengthened in all groups as the
S1-S2 interval shortened but to varying degrees. Thus, at the shortest
Fig. 5. Plots of mean ± SEM (a) (dV/dt)max, (b) AP latency and (c) time to 90% AP recovery (APD90) and (d) AP wavelength for APs obtained in response to S2 stimuli (i) through the
range of coupling intervals explored, reducing from 89 ms to 30 ms. Panel (ii) for each provides a comparison of these values at the beginning and termination of the pacing protocol,
corresponding to a refractory outcome or the onset of sustained arrhythmia. The symbols denote signiﬁcant diﬀerences between each pair, obtained from post hoc Tukey testing, which
was conducted if the ANOVA indicated a signiﬁcant outcome. Single, double and triple symbols denote p < 0.05, p < 0.01 and p < 0.001 respectively.
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S1-S2 intervals, a signiﬁcant diﬀerence between WT and Pgc-1β−/−
hearts persisted (F= 10.15, p < 0.001); however signiﬁcant eﬀects of
age (F= 1.19, p > 0.05) or interaction (F= 2.79, p > 0.05) were no
longer evident. AP latency times remained signiﬁcantly shorter in
young WT hearts when compared with young Pgc-1β−/− (p < 0.01)
and aged Pgc-1β−/− hearts (p < 0.05); however the lengthening of AP
latency in aged WT was less pronounced than that of the Pgc-1β−/−
hearts and thus the diﬀerence with the young WT hearts was no longer
signiﬁcant.
The adaptation of AP duration, given by APD90 values, through
progressively shortening S1–S2 coupling intervals is shown in Fig. 5(c
(i)). Overall APD90 times did not diﬀer between experimental groups
(ANOVA – genotype: F= 2.95, p > 0.05; age: F= 1.71, p > 0.05;
interaction: F= 0.002, p > 0.05), reﬂecting the ﬁndings during reg-
ular 8 Hz pacing. Accordingly, APD90 times at the beginning of the
protocol, corresponding to the longest S1-S2 intervals, also did not
diﬀer between groups (ANOVA – genotype: F= 1.63, p > 0.05; age:
F= 0.02, p > 0.05; interaction: F= 1.30, p > 0.05). APD90 times in
all groups displayed the expected shortening as the S1-S2 interval de-
creased; however a small but signiﬁcant diﬀerence in APD90 between
WT and Pgc-1β−/− hearts was seen at the shortest coupling intervals
(F= 6.60, p < 0.05), where Pgc-1β−/− hearts had shorter APD90. No
diﬀerences were noted based upon age (F= 0.02, p > 0.05), or in-
teracting eﬀects of genotype and age (F= 1.52, p > 0.05). There were
no signiﬁcant diﬀerences between groups on post hoc Tukey testing.
Reductions in the AP wavelength have been suggested to correlate
with increased arrhythmic risk, indicating the presence of substrate
favorable to AP re-entry (Davidenko et al., 1995; Krogh-Madsen et al.,
2012; Pandit and Jalife, 2013; Weiss et al., 2005). It has previously
been calculated from terms relating to AP conduction and AP duration
(Matthews et al., 2013), and similar analyses were conducted in the
present study. Pgc-1β−/− hearts had signiﬁcantly shorter wavelength
values at resting hearts as measured during 8 Hz pacing (F= 20.62,
p < 0.001), however there were no eﬀects of ageing (F= 0.01,
p > 0.05) or interacting eﬀects of the two variables (F= 0.32,
p> 0.05) (Table 2). AP wavelength proﬁles for beats triggered by S2
extrastimuli during PES pacing are shown in Fig. 5(d). Wavelengths
were shorter throughout the protocol in Pgc-1β−/− hearts (F= 9.19,
p < 0.01), with no independent eﬀect of age (F= 0.03, p > 0.05) or
interacting eﬀects of genotype and age (F= 0.01, p > 0.05). The
diﬀerences between WT and Pgc-1β−/− hearts noted during regular
8 Hz pacing was similarly evident at the longest S1-S2 intervals
(F = 18.93, p < 0.01) with no other signiﬁcances noted (ageing:
F = 0.01, p > 0.05; genotype – age interaction: F = 1.20, p > 0.05)
(Fig. 5(d(ii))). Post hoc Tukey tests revealed signiﬁcant diﬀerences
between young WT and aged Pgc-1β−/− hearts (p < 0.05), aged WT
and young Pgc-1β−/− hearts (p < 0.01), and aged WT and aged Pgc-
1β−/− hearts (p < 0.01). Wavelength values were reduced in all
groups as the S1-S2 coupling interval shortened, correlating with the
increased vulnerability to arrhythmias seen in all hearts. However, AP
wavelengths for young Pgc-1β−/− hearts more closely converged to
those of both WT groups, whereas wavelengths remained shorter in
aged Pgc-1β−/− hearts. Thus though Pgc-1β−/− hearts continued to
display signiﬁcantly shorter wavelengths at the shortest S1-S2 intervals
(ANOVA – genotype: F = 5.00, p < 0.05; age: F = 0.51, p > 0.05,
interaction: F= 2.40, p > 0.05), no signiﬁcant diﬀerences were noted
between any groups on post hoc testing.
3.4. Relative changes in action potential parameters following premature
extrasystolic stimuli
The energetic dysfunction associated with mitochondrial impair-
ment would be expected to particularly compromise cardiac activity in
the stressed state. Indeed Pgc-1α deﬁcient hearts show normal con-
tractile function at baseline but develop pronounced cardiac failure in
response to aortic banding. Pgc-1β−/− hearts are known to develop
chronotropic incompetence in response to adrenergic challenge despite
normal resting heart rates. To further characterise the cardiac pheno-
type in response to increasing metabolic demand in the form of short-
ening pacing intervals, electrophysiological parameters during PES
pacing were normalised internally to their corresponding values mea-
sured during regular 8 Hz pacing. The normalised proﬁles for the re-
levant parameters are shown in Fig. 6(a–c). Normalised (dV/dt)max
(Fig. 6a) and normalised APD90 values (Fig. 6c) displayed similar re-
ductions with shortening S1-S2 intervals, and there were no signiﬁcant
diﬀerences in AUC values for either parameter (Table 4). Despite dif-
fering absolute AP latency times, normalised AP latency proﬁles for
young and aged WT hearts were similar (Fig. 6(b)). In contrast Pgc-1β−/
− hearts displayed greater increments in normalised latency with
shortening S1-S2 intervals, with aged Pgc-1β−/− hearts appearing most
compromised. ANOVA analysis of AUC values for normalised AP la-
tency showed no independent eﬀects of genotype (F= 0.49, p > 0.05)
or age (F= 0.05, p > 0.05), but a signiﬁcant interacting eﬀect of the
two (F= 4.31, p < 0.05) with aged Pgc-1β−/− hearts having the
highest AUC values. No signiﬁcant diﬀerences were seen on individual
comparisons with post hoc Tukey testing.
3.5. Contrasting impacts of (dV/dt)max upon AP latency in WT and Pgc-
1β−/− hearts
Findings from the regular 8 Hz and PES pacing protocols suggested
an arrhythmic substrate in Pgc-1β−/− hearts through compromised
conduction parameters, with few alterations in repolarisation char-
acteristics. Here, Pgc-1β−/− hearts displayed deﬁcits in (dV/dt)max that
were independent of age, and a corresponding altered conduction
through the myocardium, reﬂected by prolonged AP latency times.
However, the latter, diﬀered from (dV/dt)max, in appearing to be in-
ﬂuenced by age to some degree. This prompted further exploration of
the relationship between these conduction parameters. Mean AP la-
tency times from extrasystolic S2 beats recorded during the PES pro-
tocols are plotted against their corresponding mean (dV/dt)max values
for each experimental group in Fig. 7. Reductions in (dV/dt)max with
shortening S1-S2 coupling intervals is associated with increasing AP
latency times for all groups, suggesting that much of the increase in AP
latency observed with progressively shortening coupling intervals is
attributable to concurrent reductions in (dV/dt)max. However diﬀering
associations between these parameters were seen in WT and Pgc-1β−/−
hearts. As shown in Fig. 7(a), prolongation of AP latency independent of
Table 3
Area under the curve analysis for S2 triggered APs during programmed electrical stimulation.
Experimental group (dV/dt)max (V × 10−3) AP latency (ms2) APD90 (ms2) Wavelength (ms)
Young Wild Type 6.68 ± 0.32 1.06††, ‡ ± 0.04 1.06 ± 0.05 0.085 ± 0.005
Aged Wild Type 6.11 ± 0.35 1.21 ± 0.05 0.93 ± 0.06 0.082 ± 0.007
Young Pgc-1β-/- 5.44 ± 0.37 1.39†† ± 0.08 0.95 ± 0.05 0.066 ± 0.005
Aged Pgc-1β-/- 5.30 ± 0.64 1.38‡ ± 0.01 0.82 ± 0.06 0.065 ± 0.005
All values are given as mean (± SEM).
Symbols denote signiﬁcant diﬀerence based on post hoc analysis, performed if the F value from two-way ANOVA was signiﬁcant. Single, double and triple symbols denote p < 0.05,
p < 0.01 and p < 0.001 respectively.
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(dV/dt)max occurs in WT hearts with age, such that for any given (dV/
dt)max value, the AP latency time is longer in aged WT hearts compared
to young WT hearts. In contrast, young and aged Pgc-1β−/− hearts
displayed a more homogeneous association between (dV/dt)max and AP
latency, with values in line with those of aged WT hearts. Thus young
Pgc-1β−/− hearts develop electrophysiological features resembling
those of normal ageing, which may explain their increased propensity
to arrhythmia.
3.6. Compromised conduction triggering arrhythmia in all hearts
We next explored the bearing of the observed electrophysiological
parameters upon the initiation of arrhythmic events. The mean values
of the relevant electrophysiological parameters from the ﬁrst S2 AP that
triggered an episode of AT in a given heart are given in Table 5. Pgc-
1β−/− hearts showed signiﬁcantly higher values of (dV/dt)max for
triggering S2 APs compared to WT (F = 4.55, p < 0.05), but there
were no eﬀects of age (F = 0.00, p > 0.05) or interacting eﬀects of age
and genotype (F = 0.28, p > 0.05). No signiﬁcant diﬀerences were
found upon individual comparisons during post hoc analysis. Interest-
ingly, ANOVA analysis of AP latencies for the same S2 trigger APs re-
vealed no diﬀerences with respect to genotype (F = 0.001, p > 0.05),
age (F = 0.15, p> 0.05) or interaction of the two (F = 3.46,
p > 0.05). No signiﬁcant diﬀerences were seen in APD90 between
trigger S2 APs of the diﬀerent experimental groups (ANOVA – geno-
type: F= 1.02, p > 0.05; age: F= 0.37, p > 0.05; interaction:
F= 0.39, p> 0.05). Similarly AP wavelengths for trigger S2 APs were
also indistinguishable between groups (ANOVA – genotype: F= 1.96,
p > 0.05; age: F= 0.07, p > 0.05; interaction: F= 1.04, p > 0.05).
Thus AT was initiated in WT and Pgc-1β−/− hearts through premature
beats that were indistinguishable in terms of measures of conduction
across the tissue. The diﬀering proﬁles of conduction between the
groups, and the earlier development of compromise in Pgc-1β−/−
hearts may explain their increased vulnerability to arrhythmia.
Fig. 6. Plots of mean ± SEM (a) (dV/dt)max, (b) AP latency, (c) time to 90% AP recovery (APD90) in APs obtained in response to S2 stimuli, normalized to their corresponding values
obtained during regular 8 Hz pacing through progressively shortening S1-S2 coupling intervals.
Table 4
Area under the curve analysis for S2 triggered APs during programmed electrical sti-





AP latency (ms2) APD90 (ms2)
Young Wild Type 0.045 ± 0.001 0.039 ± 0.02 0.025 ± 0.001
Aged Wild Type 0.041 ± 0.002 0.035 ± 0.002 0.023 ± 0.002
Young Pgc-1β-/- 0.042 ± 0.002 0.037 ± 0.002 0.023 ± 0.001
Aged Pgc-1β-/- 0.041 ± 0.003 0.043 ± 0.003 0.023 ± 0.002
All values are given as mean (± SEM).
Symbols denote signiﬁcant diﬀerence based on post hoc analysis, performed if the F value
from two-way ANOVA was signiﬁcant. Single, double and triple symbols denote
p < 0.05, p < 0.01 and p < 0.001 respectively.
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3.7. Increased ﬁbrotic change with Pgc-1β ablation
The inﬂuence of ageing and genotype upon the relationship be-
tween rates of depolarisation and latency prompted histological as-
sessment for ﬁbrotic change. Fibrosis is known to impede AP conduc-
tion through the myocardium through decoupling of adjacent
myocytes, resulting in disrupted gap junction functioning and con-
sequent increases in resistivity. In addition, ﬁbroblast fusion with
myocytes increases membrane capacitance. Histological assessment
was conducted blindly by two investigators independently and the ICC,
a measure of consistency between their ﬁndings, was 0.88 suggesting a
high degree of consistency in the results.
Fig. 8(a) represents typical histological sections from young and
aged WT and Pgc-1β−/− hearts, the quantiﬁcation of ﬁbrotic change is
shown in Fig. 8(b). Genotype (F = 33.02, p < 0.001) and age
(F = 4.75, p < 0.05) independently increases levels of ﬁbrosis in the
atria, but there was no evidence of interaction between the two. These
ﬁndings complement the changes in latency noted in the earlier elec-
trophysiological studies. The ﬁbrotic change witnessed in WT aged
hearts compared to WT young hearts explains the increased latency
seen in this group. Young Pgc-1β−/− hearts show similar levels of ﬁ-
brosis to aged WT hearts further supporting the suggestion of premature
ageing in this group.
4. Discussion
Atrial ﬁbrillation is characterised by an irregular, often rapid atrial
rhythm that may be asymptomatic in the short term, but nevertheless
carries substantial risks of long term morbidity and mortality. Ageing
represents the major risk factor for AF itself: AF aﬀects< 0.1% in those
under the age of 50, 4% in individuals aged 60–69 and up to 20% in
those aged above 85 (Go et al., 2001; Krijthe et al., 2013; Zoni-Berisso
et al., 2014). A decline in mitochondrial function is correspondingly
observed in ageing, and has been postulated to account for age-related
decrements in organ function with associated susceptibility to disease
(Biala et al., 2015; Lane et al., 2015), including predisposition to AF (Ad
et al., 2005; Montaigne et al., 2013; Tsuboi et al., 2001). The present
study therefore investigated the electrophysiological alterations asso-
ciated with ageing and mitochondrial dysfunction in murine atria with
homozygous deﬁciency of the transcriptional co-activator Pgc-1β. We
report an age-related increase in arrhythmic incidence that was ex-
acerbated by mitochondrial dysfunction. This propensity to arrhythmia
developed predominantly through deﬁcits in parameters pertaining to
AP conduction at the cellular and tissue level.
The heart is a highly oxidative organ and served by a rich network
of mitochondria, which account for up to 30% of myocardial volume
and produce approximately 95% of its cellular ATP (Schaper et al.,
1985). Understandably mitochondrial dysfunction is associated with
altered cardiac electrical properties, giving rise to AP heterogeneities
that provide a substrate for arrhythmia, and has been the subject of
much attention in the context of ventricular arrhythmogenesis (Brown
and O’Rourke, 2010; Yang et al., 2014). Mitochondrial abnormalities
have also been reported in studies of AF but their role in its patho-
genesis have been relatively unexplored. Evidence of altered mi-
tochondrial structure was found in dog (Morillo et al., 1995) and goat
(Ausma et al., 1997) models of AF. Here, AF was induced by rapid atrial
pacing with the noted mitochondrial defects appearing as a possible
consequence of the pacing protocol and/or AF itself. Similarly, evidence
of mitochondrial abnormalities have been reported in tissue samples
obtained during cardiac surgery from AF patients (Emelyanova et al.,
2016; Lin et al., 2003; Slagsvold et al., 2014; Tsuboi et al., 2001). In
these studies the selected cohorts had established AF and it remains
diﬃcult to distinguish whether the observed mitochondrial lesions
were caused by or resulted from AF, or indeed were a confound of
ageing or other age-related conditions associated with metabolic com-
promise. However baseline mitochondrial deﬁcits were found to predict
Fig. 7. Dependences of AP latency times upon (dV/dt)max through the programmed electrical stimulation protocol compared in (a) young and old WT and (b) young and aged Pgc-1β−/−
hearts.
Table 5
AP parameters for S2 triggered APs that initiated the ﬁrst episode of atrial tachycardia during programmed electrical stimulation.
Experimental group (dV/dt)max (V s−1) AP latency (ms) APD90 (ms) Wavelength
Wild Type Young 100.10 ± 5.68 27.42 ± 1.52 15.96 ± 0.50 1.58 ± 0.10
Wild Type Aged 112.53 ± 10.63 33.90 ± 3.39 17.60 ± 3.59 1.98 ± 0.44
Pgc-1β-/- Young 142.03 ± 11.77 32.86 ± 1.77 15.17 ± 0.61 2.12 ± 0.16
Pgc-1β-/- Aged 137.46 ± 14.65 28.57 ± 2.56 15.43 ± 0.85 2.04 ± 0.18
All values are given as mean (± SEM).
Symbols denote signiﬁcant diﬀerence based on post hoc analysis, performed if the F value from two-way ANOVA was signiﬁcant. Single, double and triple symbols denote p < 0.05,
p < 0.01 and p < 0.001 respectively.
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development of post-operative AF following cardiac surgery in patients
with no prior history of AF (Ad et al., 2005; Montaigne et al., 2013),
suggesting a more direct role in its pathogenesis. Furthermore, Marks
and colleagues recently reported that diastolic Ca2+ leak, through
progressive oxidation of ryanodine receptors, was associated with age-
dependent development of AF in a murine model (Xie et al., 2015).
Reductions in mitochondrial ROS production attenuated these diastolic
Ca2+ transients and prevented AF.
Electrophysiological alterations secondary to chronic mitochondrial
impairment have not been well characterised to date. The PGC-1 family
of transcriptional coactivators, which includes PGC-1α and PGC-1β,
serve as key modulators of cellular metabolic activity, particularly in
oxidative tissues such as the heart and brain (Riehle and Abel, 2012).
Their present study combines the hitherto separate use of murine car-
diac models in metabolic and electrophysiological studies. First, these
demonstrated that Pgc-1α and Pgc-1β murine models do replicate the
clinically reported energetic changes. Both Pgc-1α-/- (Arany et al.,
2005; Huss et al., 2004; Vega et al., 2000) and Pgc-1β-/- mice (Lelliott
et al., 2006) showed blunted expression of oxidative phosphorylation
genes and reduced mitochondrial enzymatic activities, capacities for
mitochondrial ATP synthesis and cytosolic ATP levels. Conversely,
overexpression in speciﬁc Pgc-1 family members increased expression
of nuclear and mitochondrial genes, mitochondrial density and their
oxidative capacity (Lehman et al., 2000; Russell et al., 2004).
Secondly, murine models have previously successfully replicated
and clariﬁed human phenotypes in arrhythmogenic conditions invol-
ving monogenic ion channel disorders. Murine hearts have similar
overall anatomies and capacities to generate polymorphic arrhythmia
(Martin et al., 2011; Matthews et al., 2013, 2012, 2010; Vaidya et al.,
1999) involving formation of drifting rotors generating scroll waves
even in their small volumes of tissue, as in human hearts (Gray et al.,
1995). Mouse cardiac, particular ventricular AP waveforms show
shorter, triangulated recovery waveforms distinct from those in hu-
mans, reﬂecting diﬀering contributions from the various K+ current
subtypes. Nevertheless, APs of mouse atria and ventricles resemble
those of human hearts in their rapid depolarisation phases driven by
inward INa (Guo et al., 1999) and their resulting transmural AP con-
duction velocities (Higuchi and Nakaya, 1984; Liu et al., 2004).
Fig. 8. (a) Representative images of histological samples used for
morphological assessment of ﬁbrotic change. (b) The degree of
ﬁbrotic change was assessed as the proportion of morphometric
squares covering tissue that demonstrated evidence of ﬁbrosis as
detected by picrosirius red staining. The numbers of hearts ex-
amined: young WT (n = 6), aged WT (n = 6), young Pgc-1β−/−
(n = 6), aged Pgc-1β−/− (n = 6). Symbols denotes pairs of points
showing signiﬁcant diﬀerences from post hoc Tukey testing,
where single, double and triple symbols denote p < 0.05,
p < 0.01 and p < 0.001 respectively. (For interpretation of the
references to colour in this ﬁgure legend, the reader is referred to
the web version of this article).
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Monogenic murine cardiac models successfully demonstrated clinically
observed atrial and ventricular arrhythmic phenotypes and their me-
chanisms following loss of Scn5a function replicating Brugada Syn-
drome and following challenge by class I, Na+ channel blocking drugs,
both situations compromising AP conduction (Dautova et al., 2010;
Guzadhur et al., 2013; Martin et al., 2012).
Thirdly, deﬁciencies in either or both Pgc-1α and Pgc-1β do induce
cardiac phenotypes. Mice deﬁcient in both genes develop a lethal low
cardiac output state and conduction system disease (Lai et al., 2008).
Finally, Pgc-1β deﬁciency is not associated with cardiac dysfunction at
baseline (Lelliott et al., 2006), but is associated with increased sus-
ceptibility to ventricular arrhythmias (Gurung et al., 2011). This makes
it an appropriate model to investigate electrophysiological alterations
secondary to mitochondrial dysfunction in murine atria. The modiﬁed
Langendorﬀ preparation utilised here permitted simultaneous volume
conductor ECG and intracellular microelectrode recordings during
regular pacing and programmed electrical stimulation applying pre-
mature extra stimuli, enabling assessment of AP activation and recovery
properties
Hearts were ﬁrst paced at a frequency of 8 Hz, reﬂecting murine
resting heart rates and therefore providing steady state electro-
physiological characterisation. No arrhythmias were observed in any
group during regular pacing. This is consistent with previous reports
that Pgc-1β ablation is not associated with a pronounced cardiac phe-
notype under conditions of baseline activity. In contrast arrhythmias
were seen in all experimental groups during programmed electrical
stimulation. Incidences of arrhythmia increased with age in both WT
and Pgc-1β−/− hearts, in keeping with the cumulative risk of both atrial
and ventricular arrhythmias with age seen in the clinical setting (Deo
and Albert, 2012; Zoni-Berisso et al., 2014). Young WT hearts displayed
the fewest episodes of AT of all groups, and the incidence was higher in
aged WT hearts. The mitochondrial theory of ageing posits progressive
deterioration in mitochondrial function, through accumulation of mu-
tations in mitochondrial DNA and impaired autophagy, underpinning
the ageing process and may contribute to this increased vulnerability to
arrhythmia. Accordingly Pgc-1β−/− hearts, possessing a pronounced
mitochondrial defect, had even higher incidences of AT. Here aged Pgc-
1β−/− hearts displayed the greatest propensity to arrhythmia of all
groups, in terms of the proportion of hearts that were arrhythmic and
the overall number of episodes of arrhythmia.
The electrophysiological alterations underlying the greater pro-
pensity to arrhythmia in Pgc-1β−/−− hearts were examined with in-
tracellular AP recordings from the left atrium, which suggested that
these occurred primarily through abnormalities in AP conduction. At
the cellular level, young and aged Pgc-1β−/− hearts had signiﬁcantly
reduced (dV/dt)max values compared to WT hearts during regular pa-
cing. There was no diﬀerence in (dV/dt)max based upon age in either
group. A similar pattern was also observed in APs triggered by S2 sti-
muli during the PES protocol. As would be expected, (dV/dt)max values
progressively reduced with shortening of the coupling interval in all
groups. At the longest coupling intervals (dV/dt)max values diﬀered
between WT and Pgc-1β−/− hearts to similar extents as during 8 Hz
pacing, whereas they converged to become indistinguishable at the
shortest coupling intervals. Thus Pgc-1β−/− hearts demonstrated
compromise at modest levels of stress represented by the longer cou-
pling intervals, and correlated with their increased susceptibility to
arrhythmia through greater parts of the protocol.
Reduced atrial conduction velocities have been reported as an early
feature in patients with AF (Zheng et al., 2016) and potentially play a
signiﬁcant role in providing a substrate for its maintenance in the long
term (Miyamoto et al., 2009; Park et al., 2009). Values of (dV/dt)max are
known to correlate with peak Na+ currents (INa) (Hondeghem and
Katzung, 1977) and conduction velocity in skeletal and cardiac cells
(Fraser et al., 2011; Usher-Smith et al., 2006). Thus, INa dominates over
Ca2+ current, ICa, as the dominant inward, depolarising, current in
atrial cardiomyocytes. It accounts for signiﬁcantly greater maximum
conductances (7.8 nS/pF vs. 0.12 nS/pF (Van Wagoner et al., 1999))
and maximum currents (∼85 pA/pF (Burashnikov et al., 2007; Sossalla
et al., 2010) vs. ∼6 to 9 pA/pF (Carnes et al., 2007; Courtemanche
et al., 1998)), at voltages corresponding to the most rapidly rising phase
of the action potential (–30 mV vs +10 mV (Van Wagoner et al.,
1999)). Time-dependent reductions in INa and consequent reductions in
atrial conduction velocity have previously been implicated in the pa-
thogenesis in a canine model of AF (Gaspo et al., 1997a). Furthermore
SCN5A gene variants, which encodes the cardiac sodium channel re-
sponsible for the inward Na+ current, are associated with increased risk
of developing AF (Darbar et al., 2008; Olson et al., 2005).
Mitochondrial dysfunction can alter INa through a number of po-
tential mechanisms. Firstly reductions in INa in cardiomyocytes were
observed in response to metabolic stress (Liu et al., 2009) and could be
recovered with application of the mitochondrial ROS scavenger mito-
TEMPO (Liu et al., 2010). Secondly, ﬂuctuations in cytosolic [Ca2+]
could also potential modify sodium channel properties through binding
in its C-terminal region, either directly at an EF hand motif (Wingo
et al., 2004) and indirectly through an IQ domain sensitive to calmo-
dulin/calmodulin kinase II (Mori et al., 2000). Elevated intracellular
[Ca2+] caused reductions in INa density and (dV/dt)max in cardiomyo-
cytes in vitro (Casini et al., 2009), and in whole hearts following dia-
stolic Ca2+ leaks, through application of caﬀeine (Zhang et al., 2009),
known to increase diastolic Ca2+ release, or mutations associated with
diastolic Ca2+ release (Glukhov et al., 2013; King et al., 2013b; Li et al.,
2014). Abnormal diastolic Ca2+ transients have been recorded in car-
diomyocytes in Pgc-1β−/− hearts (Gurung et al., 2011).
The conduction of an AP wavefront through tissue is inﬂuenced by
the membrane capacitance and its resistance, in addition to (dV/dt)max
(Jeevaratnam et al., 2011; King et al., 2013a). Conduction was there-
fore further assessed through evaluation of AP latency times. These
were signiﬁcantly prolonged in Pgc-1β−/− hearts compared to WT
during regular pacing, with young WT hearts having signiﬁcantly
shorter AP latency durations than any other experimental group in-
cluding aged WT hearts. During PES pacing, AP latency times increased
with shortening of the S1-S2 coupling interval in all groups, but with
diﬀering magnitudes. Conduction slowing was most pronounced in Pgc-
1β−/− hearts, particularly aged Pgc-1β−/− hearts, at the shorter cou-
pling intervals correlating with their greater vulnerability to ar-
rhythmia during the PES protocols. The diﬀering comparisons of (dV/
dt)max and AP latency between groups were further explored by eval-
uating the dependence of AP latency upon (dV/dt)max within groups. In
all cases AP latency lengthened with reductions in (dV/dt)max, in
keeping with the known relationship between (dV/dt)max, INa and
conduction velocity (Hunter et al., 1975). However young and aged WT
hearts displayed distinct relationships between AP latency and (dV/
dt)max, with age-related delays in latency observed at any given (dV/
dt)max value. In contrast this correlation was indistinguishable between
young and aged Pgc-1β−/− hearts, where both resembled the conduc-
tion slowing seen with ageing in WT hearts.
Myocardial ﬁbrosis is associated with increased tissue capacitance
and resistance, contributing to conduction slowing independent of the
inﬂuence of (dV/dt)max and may explain the conduction properties
described in the present study. Fibrotic change is thought to be a key
element of the remodeling seen in AF (Frustaci et al., 1997; Kostin et al.,
2002). Progressive ﬁbrosis is a common feature of cardiac ageing in
animal (Eghbali et al., 1989; Jeevaratnam et al., 2012; Lin et al., 2008;
Orlandi et al., 2004) and human (Gazoti Debessa et al., 2001) studies.
Age-dependent ﬁbrosis was similarly recorded in the present study, in
both WT and Pgc-1β−/− hearts, and mitochondrial dysfunction through
Pgc-1β ablation was associated with a further additive eﬀect on the
degree of ﬁbrosis. Aged Pgc-1β−/− hearts therefore displayed the
greatest degree of ﬁbrosis whereas young WT hearts had the least and
AP latency times correlated with the observed degrees of ﬁbrosis in the
respective groups.
The ﬁbrosis-mediated reductions in cardiac conduction reported
H. Valli et al. Mechanisms of Ageing and Development 167 (2017) 30–45
41
here could potentially occur through increased coupling of ﬁbroblasts
to cardiomyocytes through Cx43 and/or Cx45, thereby increasing
membrane capacitance (Camelliti et al., 2004; Chilton et al., 2007; Van
Veen et al., 2005). More direct disruption of gap junctions has also been
reported consequently increasing tissue resistance, further slowing
conduction (Xie et al., 2009). Interestingly, mice lacking the mi-
tochondrial sirtuin SIRT3 display augmented mitochondrial ROS pro-
duction and enhanced cardiac ﬁbrosis (Hafner et al., 2010). Upregu-
lated antioxidant capacity through a mitochondrial speciﬁc
overexpression of catalase protected against features of cardiac ageing
including myocardial ﬁbrosis (Dai et al., 2009). Furthermore, trans-
forming growth factor-β1 (TGF-β1) is thought to have a signiﬁcant role
in age-related myocardial ﬁbrosis (Brooks and Conrad, 2000;
Rosenkranz et al., 2002). Mice over expressing TGF-β1 develop pro-
nounced atrial ﬁbrosis, have reduced atrial conduction velocities and
greater inducibility to atrial tachyarrhythmias including AF (Verheule
et al., 2004). Serum levels of TGF-β1 are increased in individuals with
AF compared to control (Lin et al., 2015). TGF-β1 activity is also en-
hanced by oxidative stress (Barcellos-Hoﬀ and Dix, 1996; Sullivan et al.,
2008).
A pro-arrhythmic substrate can also develop through altered re-
polarisation properties including reductions in the APD or shortening of
the atrial ERP. Reductions in APD have been documented in AF and
were also seen in the present study, consistent with the previously re-
ported eﬀect of mitochondrial dysfunction upon AP repolarisation
properties (Brown and O’Rourke, 2010). However these were witnessed
in aged Pgc-1β−/− hearts and most pronounced at shorter S1–S2 cou-
pling intervals in the PES protocol and would favour re-entry and
arrhtymogenesis. These parameters pertaining to AP recovery can be
combined with those of AP activation to give the AP wavelength, de-
ﬁned as the distance travelled by the depolarising wave over one re-
fractory period (Allessie et al., 1977). Shortening of the AP wavelength
favours re-entry whereas its lengthening is thought to be protective
(Davidenko et al., 1995; Pandit and Jalife, 2013; Spector, 2013; Weiss
et al., 2005; Zaitsev et al., 2000) AP wavelength was shorter in Pgc-1β−/
− hearts than WT heart, both at circumstances mimicking resting heart
rates and PES pacing. With reductions in the S1-S2 coupling interval,
the shorter AP wavelengths in aged Pgc-1β−/−hearts persisted, whereas
those for young Pgc-1β−/− hearts and WT hearts overlapped, corre-
lating with the diﬀering arrhythmic susceptibilities observed in the
present study.
Finally, the inﬂuence of these electrophysiological parameters upon
arrhythmia induction was examined in the ﬁrst S2 AP that provoked an
episode of AT in each heart. Interestingly (dV/dt)max values were higher
for S2 beats triggering AT in Pgc-1β−/− hearts than WT hearts; however
no diﬀerence was seen in AP latency times. Thus the higher (dV/dt)max
values of Pgc-1β−/− hearts appear to oﬀset the increased ﬁbrotic
changes in these hearts, which therefore achieve a similar overall
conduction velocity. Similarly, no diﬀerence in APD90 or AP wave-
length were seen in S2 beats triggering arrhythmias in WT and Pgc-1β−/
− hearts. This suggested critical electrophysiological thresholds
common to all groups, below which the susceptibility to arrhythmias is
increased. The diﬀering parameters measured in the current experi-
ments indicate these circumstances arise earlier through ageing and
mitochondrial dysfunction, thus widening the range of S1-S2 intervals
at which the Pgc-1β−/− hearts were at risk of arrhythmia compared to
WT hearts. Accordingly, the critical coupling intervals were longer in
Pgc-1β−/− hearts compared to WT hearts, and in particular in aged Pgc-
1β−/− hearts.
5. Conclusion
Together, the present experiments associate an atrial arrhythmic
phenotype secondary to a chronic mitochondrial deﬁcit, modeled by in
murine Pgc-1β−/− hearts. This is attributable to maladaptive altera-
tions in action potential conduction arising from electrophysiological
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